16.50
-0.73(-4.24%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
111
First IPO Date
March 20, 2014
| Name | Title | Pay | Year Born |
| Ofer Gonen | Chief Executive Officer | 850,000 | 1973 |
| Yaron Meyer Adv. | Executive Vice President, General Counsel & Corporate Secretary | 318,000 | 1979 |
| Ety Klinger | Chief Research & Development Officer | 384,000 | 1962 |
| Hani Luxenburg | Chief Financial Officer | 395,000 | 1973 |
| Shmulik Hess | Chief Operating Officer & Chief Commercial Officer | 430,000 | 1973 |
| Liron Gal | Vice President of Manufacturing Science & Technology | 0 | N/A |
| Robert J. Snyder | Chief Medical Officer | 0 | 1950 |
| Barry J. Wolfenson | Executive Vice President of Strategy & Corporate Development | 0 | 1967 |
| Hagit Mashiach | VP of Human Resources | 0 | N/A |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.